These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 22043059)

  • 1. New omics information for clinical trial utility in the primary setting.
    Damia G; Broggini M; Marsoni S; Venturini S; Generali D
    J Natl Cancer Inst Monogr; 2011; 2011(43):128-33. PubMed ID: 22043059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
    Generali D; Berruti A; Foroni C; Bazzola L; Andreis D; Allevi G; Bersiga A; Dogliotti L; Fox SB; Harris AL; Bottini A
    J Natl Cancer Inst Monogr; 2011; 2011(43):67-70. PubMed ID: 22043044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Better translation from bench to bedside: breakthroughs in the individualized treatment of cancer.
    Straehle C; Cardoso F; Azambuja E; Dolci S; Meirsman L; Vantongelen K; Ignatiadis M; Sotiriou C; Piccart-Gebhart MJ
    Crit Care Med; 2009 Jan; 37(1 Suppl):S22-9. PubMed ID: 19104222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
    Conte P; Guarneri V; Bengala C
    Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Strategies of breast cancer treatment based on determination of biological subtype].
    Semiglazov VF
    Vopr Onkol; 2011; 57(5):542-52. PubMed ID: 22238922
    [No Abstract]   [Full Text] [Related]  

  • 7. "Omics" in pharmaceutical research: overview, applications, challenges, and future perspectives.
    Yan SK; Liu RH; Jin HZ; Liu XR; Ye J; Shan L; Zhang WD
    Chin J Nat Med; 2015 Jan; 13(1):3-21. PubMed ID: 25660284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 9. Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors.
    Tuma RS
    J Natl Cancer Inst; 2012 Jul; 104(13):968-9. PubMed ID: 22745473
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmaco-metabolomics: an emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets.
    Corona G; Rizzolio F; Giordano A; Toffoli G
    J Cell Physiol; 2012 Jul; 227(7):2827-31. PubMed ID: 22105661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
    Metzger-Filho O; de Azambuja E
    J Natl Cancer Inst Monogr; 2011; 2011(43):116-9. PubMed ID: 22043056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of resistance to HER2 target therapy.
    Tortora G
    J Natl Cancer Inst Monogr; 2011; 2011(43):95-8. PubMed ID: 22043051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
    Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
    Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
    Burstein HJ
    Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
    Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological therapy of breast cancer: recent clinical applications.
    Baar J
    Curr Opin Investig Drugs; 2007 Dec; 8(12):987-95. PubMed ID: 18058569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A; Smith I
    Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomics of adjuvant therapy for breast cancer.
    Kim SR; Paik S
    Cancer J; 2011; 17(6):500-4. PubMed ID: 22157294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
    Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S62-6. PubMed ID: 21129613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.